[Ip-health] New Scrip Report Gives Expert Strategic Advice on How to React to Parallel Trade

[robert weissman]

New Scrip Report Gives Expert Strategic Advice on How to React to
Parallel Trade

LONDON, September 27/PRNewswire/ -- In the European Economic Area (EEA),
the practice of parallel trade in prescription medicines has been
ongoing for more than 40 years. At pharmacy buying prices, parallel
trade in the top four destination markets of the UK, Germany,
Netherlands and Sweden totals more than Euro2700 million.

It is no surprise then that the issue of parallel trade
provokes consistent hostility from pharmaceutical companies in Europe.
Yet, despite their efforts, the trade continues to flourish, eroding
profits in the freer-priced markets. Indeed, some might argue that it is
precisely because of failed efforts to stamp it out that parallel trade
has grown to affect more markets and more products than ever before.

In such an environment, it is therefore vital to coolly reassess
strategy and focus on proven techniques of tackling parallel trade that
really can maximise products' revenue. This can only follow from a
detailed understanding of the political, legal, economic and commercial
environments in which the trade occurs, and direct pre-emptive and
reactive efforts at key targets.

A new 146-page report How to React to Parallel Trade, written
by renowned parallel trade expert Donald Macarthur and published by
Scrip, provides the information required to understand this complex and
controversial issue. It gives the reader essential background
information, arguments for and against parallel trade, explanation of
the rules on bringing parallel imports to market, lessons learnt from
major controversies, country market profiles, and predictions for the
future of the practice.

Perhaps even more importantly, the report suggests strategic
responses to parallel trade and outlines their potential consequences.
It also explains price and supply management techniques and gives a
number of recommendations on how to tackle parallel trade both legally
and successfully.

This exclusive, in-depth report is a must-read for any company involved
in the manufacture and supply of prescription medicines in Europe.

About the author

Donald Macarthur is a former secretary general of the European
Association of Euro-Pharmaceutical Companies (EAEPC), the pan-European
grouping of national associations and individual firms involved in
parallel trading of medicines. He has produced 40+ reports on
pharmaceutical business issues and his consultancy clients have included
EFPIA, PhRMA and GIRP. He worked for 16 years in the pharmaceutical
industry and is listed in Marquis' Who's Who in the World. He is
considered by many to be the leading expert on pharmaceutical parallel
trade.

Scrip Reports publishes an extensive range of pharmaceutical
therapeutic market reports, detailed analyses of the pharmaceutical
market for specific geographic areas, in-depth profiles of companies
operating in the industry, financial and statistical analyses,
directories and other strategic reports on the healthcare sector.

Visit http://www.scripreports.com/paralleltrade for more information.

For further press details contact
Jenefer Trevena
Managing Editor
Scrip Publishing
Tel: +44-(0)-20-7017-6989
Email: jenefer.trevena@informa.com.

To purchase How to React to Parallel Trade contact
Andrew Maitland
Sales Manager
Tel: +44-(0)-20-7017-6859
Email: andrew.maitland@informa.com and quote code JR20002P